Cypherpunk Technologies just reported a $39.4 million net income for Q2 2026, a dramatic reversal from the $16.6 million loss it posted in the same period a year earlier. The catalyst: a $46 million unrealized gain on its Zcash holdings.
A pharma company turned crypto treasury
Cypherpunk Technologies, which trades on NASDAQ under the ticker CYPH, formerly operated as Leap Therapeutics, an oncology-focused biotech firm. It rebranded in November 2025 and pivoted toward a ZEC-centric treasury strategy, though it reportedly still maintains its legacy oncology research assets.
The pivot was backed by serious money. Winklevoss Capital spearheaded a private placement that helped fund the company’s accumulation of Zcash tokens.
As of early 2026, Cypherpunk is estimated to hold between 290,000 and 295,000 ZEC. That stash represents roughly 1.7% to 1.76% of Zcash’s total circulating supply, acquired at an average price somewhere in the $334 to $336 range per token. At recent valuations, the position is worth approximately $145 million.
The rollercoaster quarter-by-quarter
In Q1 2026, Cypherpunk posted a net loss of $77.2 million. The culprit was a $77.6 million unrealized loss as Zcash’s price cratered from around $508 to approximately $240.
For the full year of 2025, Cypherpunk managed to report a net income of $4.8 million, which was itself a recovery from a $67.8 million loss in 2024. That 2025 turnaround was powered by about $50.4 million in unrealized gains from its crypto holdings.
Why Zcash, and why it matters
Zcash occupies a specific niche in the crypto ecosystem. It’s a privacy coin that uses zero-knowledge proofs — a cryptographic technique that lets you prove something is true without revealing the underlying data — to enable shielded transactions.
For investors considering CYPH as a proxy for Zcash exposure, the key question is whether the public market wrapper adds enough value — liquidity, accessibility in brokerage accounts, potential tax advantages — to justify the corporate overhead and governance risk. What’s worth watching next is whether ZEC’s price holds above the company’s average acquisition cost of roughly $335. If it dips below that level again, the unrealized losses could make Q1’s $77 million hit look modest by comparison.